SFB 1399

Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer

20 Research Projects:

Interdisciplinary, Cross-Faculty Collaboration

SFB1399

News

See all News…

Small cell lung cancer (SCLC) is the most aggressive lung cancer subtype and little progress has been made in understanding the molecular mechanisms causing this devastating disease. No mechanistic explanation exists for a central clinical hallmark: While SCLC typically presents with initial sensitivity against chemotherapy, the disease almost inevitably relapses. Recent discoveries in SCLC genomics and transcriptomics have now provided first mechanistic insight into the biology of this deadly disease. 

Latest Publications

  • Oncogenic KRAS-driven type I interferon signalling primes pancreatic cancer for necroptosis.
    Tishina S, Dahlhaus A, Manik M, Mulalic L, Murr J, Kotliar M, Rakhsh-Khorshid H, Kostopoulou M, Hocher F, Stroh J, Beck J, Williams RM, Balta GG, Liu F, Abdallah AT, Bebber CM, Reese M, Lim JKM, Quaas A, Brägelmann J, Pasparakis M, Beleggia F, Balachandran S, Trauzold A, Liccardi G, Astsaturov I, Reichert M, Androulidaki A, von Karstedt S. Nat Commun. 2026 Jun 15;17(1):5288. doi: 10.1038/s41467-026-73189-8. PMID: 42297776; 
    PMCID: PMC13269921.
  • Cancer neuroscience: The past, the present, and the road ahead.
    Winkler F, Heuer S, Althammer F, Augustin H, Beleggia F, Demir IE, Koenig J, Kuner R, Kuner T, Loges S, Platten M, Reinhardt HC, Rich JM, Sahm F, Stassart RM, Thiel V, Trumpp A, Venkataramani V, Wick W, Karreman MA. Cell. 2026 Apr 16;189(8):2464-2489. doi: 10.1016/j.cell.2026.03.018.
    PMID: 41997131.
  • Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy. 
    Samarin J, Nůsková H, Fabrowski P, Malz M, Amtmann E, Taeubert MJ, Pastor-Flores D, Kazdal D, Kurilov R, de Vries N, Pink H, Deis F, Hummel-Eisenbeiss J, Renz L, Kaushal K, Morgen M, Dick TP, Hamilton G, Muckenthaler M, Mall M, Lim B, Kanamaru T, Klinke G, Sos ML, Frede J, Miller AK, Alborzinia H, Gunkel N. Nat Commun. 2026 Apr 12;17(1):3435. doi: 10.1038/s41467-026-71608-4. 
    PMID: 41965332.
  • Telomere damage enhances immunogenicity of neuroblastoma and accelerates response to anti-PD-L1 treatment. 
    Oncoimmunology. 
    Höppner S, Werr L, Szilagyi B, Bartenhagen C, Hellmann AM, Rosswog C, Linden E, Primke G, Kahlert Y, Ibruli N, Hemstedt N, Lorenz W, Brägelmann J, Hölzel M, Fischer M. 2026 Dec 31;15(1):2653918. doi: 10.1080/2162402X.2026.2653918. Epub 2026 Apr 8. 
    PMID: 41948996.
  • A feedback loop between cell proliferation and ROS regulates ferroptosis sensitivity. Seidel E, Itak EY, Müller F, Yapici FI, Brägelmann J, Berg J, von Karstedt S. Front Cell Dev Biol. 2026 Mar 25;14:1756238. doi: 10.3389/fcell.2026.1756238. PMID: 41960191;
    PMCID: PMC13059718.
  • Lysine-11 ubiquitination drives type-I/III interferon induction by cGAS-STING and Toll-like receptors 3 and 4. 
    Betrancourt A, Cinko MT, Varanda AB, Arias M, Uranga-Murillo I, Peña N, Kaps LM, Chau LF, Buratti B, Brägelmann J, de Miguel D, Becker K, Casper R, Martin R, Alcami A, Ferguson BJ, Pardo J, Rieser E, Walczak H. Nat Cell Biol. 2026 Mar;28(3):608-621. doi: 10.1038/s41556-026-01886-z. Epub 2026 Mar 6. PMID: 41792265; 
    PMCID: PMC12992118.
  • A disease model resource reveals core principles of tissue-specific cancer evolution. 
    Mueller S, de Andrade Krätzig N, Tschurtschenthaler M, Silva MG, Thordsen C, Trozzo R, Simon P, Saab F, Kaltenbacher T, Zukowska M, Lucarelli D, Öllinger R, Griger J, Groß N, Groll T, Löprich J, Zaurito AE, Schömig LR, Bugter JM, Bärthel S, Falcomatà C, Strong A, Brandt C, Najajreh M, Papargyriou A, Maresch R, Collins KAN, Sailer D, Schneeweis C, Burger S, Fröhlich LM, Klement C, Belka A, Montero JJ, Jungwirth U, Reichert M, Moser M, Neumann J, Vassiliou G, Cadiñanos J, Varela I, Marr C, Alonso DF, Lollini PL, Zhao J, Chesler L, Isacke CM, Riedel A, Braun CJ, Sos ML, Beleggia F, Reinhardt HC, Musteanu M, Barbacid M, Quante M, Schmidt-Supprian M, Schneider G, Clare S, Lawley TD, Dougan G, Steiger K, Conte N, Bradley A, Rad L, Saur D, Rad R. Nature. 2026 Feb 25. doi: 10.1038/s41586-026-10187-2. Epub ahead of print. 
    PMID: 41741657.
  • Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma. 
    Werr L, Boland J, Petersen J, Iglesias F, Höppner S, Bartenhagen C, Rosswog C, Hellmann AM, Kahlert Y, Hemstedt N, Ibruli N, Dammert MA, Decarolis B, Werner JM, Malchers F, Schramm K, Witt O, Beiske KH, Rognlien AGW, Gunnes MW, Langenberg KP, Molenaar J, Bernkopf M, Taschner-Mandl S, Hughes D, George SL, Chesler L, Schulte JH, Barone G, Capasso M, Surrey LF, Bagatell R, Masliah-Planchon J, Schleiermacher G, Grüll H, Westermann F, Schultheis AM, Büttner R, Henssen AG, Eggert A, Peifer M, Shukla NN, Simon T, Hero B, Reinhardt HC, Thomas RK, Fischer M. J Clin Invest. 2026 Feb 12;136(7):e189152. doi: 10.1172/JCI189152. PMID: 41678281; 
    PMCID: PMC13038208.

  • Histo-Miner: Deep learning based tissue features extraction pipeline from H&E whole slide images of cutaneous squamous cell carcinoma. 
    Sancéré L, Lorenz C, Helbig D, Persa OD, Dengler S, Kreuter A, Laimer M, Lang R, Fröhlich A, Landsberg J, Brägelmann J, Bozek K. PLoS Comput Biol. 2026 Jan 21;22(1):e1013907. doi: 10.1371/journal.pcbi.1013907. PMID: 41564120; 
    PMCID: PMC12854473.

     

See all Publications…

See all Events…

SFB 1399 Mechanisms of Drug Sensitivity and Resistance in Small Cell Lung Cancer

SFB 1399 Mechanisms of Drug Sensitivity
and Resistance in Small Cell Lung Cancer

c/o Department of Translational Genomics
University of Cologne
Weyertal 115b
50931 Cologne, Germany

+49-221-478-98776
info[@]sfb1399.de

Imprint
Privacy Policy

Partners:

University of Cologne University Hospital of Cologne University Hospital Essen TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Main University of Bonn University of Frankfurt Universitätsmedizin der Johannes Gutenberg-Universität Mainz (JGU) Ludwig-Maximilians-Universität München (LMU) Universität Stuttgart Cologne-Seoul International Research Training Group (CS-IRTG) Deutsche Forschungsgemeinschaft CIO Centrum für integrierte Onkologie Aachen Köln Bonn Düsseldorf Lung Cancer Group Cologne